ANTIGENICITY STUDY OF T-3262

We examined the antigenicity and immunological characteristics of T-3262, a new antibacterial drug. The results obtained were as follows: 1. Antibody production against T-3262 was not observed in beagles or rats treated orally with T-3262 for 28 days. 2. Antibody production against T-3262 was not ob...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 36; no. Supplement9-Base; pp. 320 - 325
Main Authors IWAI, NOBUHARU, SHIBATA, TETSUO, YONEDA, TOYOAKI
Format Journal Article
LanguageJapanese
Published Japanese Society of Chemotherapy 30.12.1988
Online AccessGet full text
ISSN0009-3165
1884-5894
DOI10.11250/chemotherapy1953.36.Supplement9-Base_320

Cover

More Information
Summary:We examined the antigenicity and immunological characteristics of T-3262, a new antibacterial drug. The results obtained were as follows: 1. Antibody production against T-3262 was not observed in beagles or rats treated orally with T-3262 for 28 days. 2. Antibody production against T-3262 was not obsearved in rabbits immunized with an emulsion of T-3262 and FREUND'S comdlete adjuvant (FCA). 3. Hapten-specific antibody production against T-3262 was demonstrated by 24-h. Passive cataneous anaphylaxis in rats, employing serum of mice immunized with a mixture of T-3262 coupled to ovalbumin and aluminium hydroxide gel. 4. No anaphylactic syndrome was observed in guinea-pigs actively sensitized with the emulsion of T-3262 and FCA. 5. T-3262 produced no positive COOMBS' test reaction.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.36.Supplement9-Base_320